Sam Fazeli

And then, of course, in small cell lung cancer, Ticentric and Druvalumab, both of them have done better than PD-1s.

And yet you have a PD-1 here that seems to be doing fine.

So that's going to be interesting.

And it does seem to me that you don't want to go and take on the king, if you want to call it, Keytruda, but to go at it in a very measured way rather than going into non-small cell lung cancer, Keynote 181 head-to-head.

But I'm looking forward to that.

I did see the press release from Henleus.

In fact, my colleagues are thinking a little bit more about it.

And so maybe when we speak again, maybe at ESMO or just after ESMO, we can have a little bit more understanding of how that data is potentially going to look or what at least the bar is.

But we're very excited by that.

So congratulations on that news too.

Oh, thank you.

No, no, I'm really intrigued by this molecule, as you can tell.

The next one I thought we could touch on is the CDK4-6.

Now, where would you put that?

Which bucket would you put that in?

I know it's not a bio, but is it a beta or a same or how would you classify that drug?

In terms of potential outside of China, of course, the complication potentially is that iBrands is heading for genericization.

And you've also got two pretty hefty competitors in the forms of Qiskali and iBrands.

Palbociclib.

So we have palbociclib, ribociclib, etc.